JP2010516290A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516290A5 JP2010516290A5 JP2009548278A JP2009548278A JP2010516290A5 JP 2010516290 A5 JP2010516290 A5 JP 2010516290A5 JP 2009548278 A JP2009548278 A JP 2009548278A JP 2009548278 A JP2009548278 A JP 2009548278A JP 2010516290 A5 JP2010516290 A5 JP 2010516290A5
- Authority
- JP
- Japan
- Prior art keywords
- regulatory
- cell
- cells
- cell epitope
- epitope polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89834707P | 2007-01-30 | 2007-01-30 | |
| US60/898,347 | 2007-01-30 | ||
| PCT/US2008/001148 WO2008094538A2 (en) | 2007-01-30 | 2008-01-29 | Regulatory t cell epitopes, compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011247226A Division JP5643739B2 (ja) | 2007-01-30 | 2011-11-11 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010516290A JP2010516290A (ja) | 2010-05-20 |
| JP2010516290A5 true JP2010516290A5 (https=) | 2011-06-16 |
| JP4866467B2 JP4866467B2 (ja) | 2012-02-01 |
Family
ID=39674696
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548278A Expired - Fee Related JP4866467B2 (ja) | 2007-01-30 | 2008-01-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2011247226A Expired - Fee Related JP5643739B2 (ja) | 2007-01-30 | 2011-11-11 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2014154372A Expired - Fee Related JP6121369B2 (ja) | 2007-01-30 | 2014-07-30 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2017064298A Expired - Fee Related JP6472476B2 (ja) | 2007-01-30 | 2017-03-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2019008352A Pending JP2019089793A (ja) | 2007-01-30 | 2019-01-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021011596A Withdrawn JP2021073255A (ja) | 2007-01-30 | 2021-01-28 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021072455A Pending JP2021107444A (ja) | 2007-01-30 | 2021-04-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021072446A Pending JP2021107443A (ja) | 2007-01-30 | 2021-04-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2022155804A Pending JP2022177270A (ja) | 2007-01-30 | 2022-09-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2024033497A Pending JP2024059975A (ja) | 2007-01-30 | 2024-03-06 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011247226A Expired - Fee Related JP5643739B2 (ja) | 2007-01-30 | 2011-11-11 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2014154372A Expired - Fee Related JP6121369B2 (ja) | 2007-01-30 | 2014-07-30 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2017064298A Expired - Fee Related JP6472476B2 (ja) | 2007-01-30 | 2017-03-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2019008352A Pending JP2019089793A (ja) | 2007-01-30 | 2019-01-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021011596A Withdrawn JP2021073255A (ja) | 2007-01-30 | 2021-01-28 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021072455A Pending JP2021107444A (ja) | 2007-01-30 | 2021-04-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021072446A Pending JP2021107443A (ja) | 2007-01-30 | 2021-04-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2022155804A Pending JP2022177270A (ja) | 2007-01-30 | 2022-09-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2024033497A Pending JP2024059975A (ja) | 2007-01-30 | 2024-03-06 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (18) | US7884184B2 (https=) |
| EP (13) | EP2423220B1 (https=) |
| JP (10) | JP4866467B2 (https=) |
| KR (3) | KR20100014871A (https=) |
| CN (4) | CN101687912B (https=) |
| AT (1) | ATE525392T1 (https=) |
| AU (1) | AU2008211227B2 (https=) |
| CA (6) | CA2963138C (https=) |
| IL (3) | IL200129A (https=) |
| MX (3) | MX347197B (https=) |
| WO (1) | WO2008094538A2 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008211227B2 (en) | 2007-01-30 | 2014-04-17 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
| DE102007030904A1 (de) * | 2007-07-03 | 2009-02-05 | Pharis Biotec Gmbh | Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| ES2618402T3 (es) * | 2011-12-13 | 2017-06-21 | Centre National De La Recherche Scientifique | Péptidos modificados y su uso para tratar enfermedades autoinmunitarias |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| US20160310584A1 (en) * | 2013-12-06 | 2016-10-27 | The Broad Institute Inc. | Formulations for neoplasia vaccines |
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| WO2016054114A1 (en) | 2014-09-29 | 2016-04-07 | The Regents Of The University Of California | Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions |
| US10213482B2 (en) | 2014-12-12 | 2019-02-26 | Immupharma France Sa | Methods of treating chronic inflammatory diseases |
| US10441649B2 (en) | 2015-02-02 | 2019-10-15 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
| WO2016179099A1 (en) | 2015-05-04 | 2016-11-10 | Epivax, Inc. | Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence |
| JP2018517405A (ja) * | 2015-05-04 | 2018-07-05 | エピバックス インコーポレーテッド | インフルエンザａ／上海／２／２０１３ ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質 |
| ES2873846T5 (en) | 2015-11-19 | 2025-06-23 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| PL238939B1 (pl) * | 2016-11-02 | 2021-10-18 | Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Im Ludwika Hirszfelda We Wrocławiu | Peptyd immunosupresyjny i jego zastosowania |
| CA3077084A1 (en) * | 2017-10-05 | 2019-04-11 | Epivax, Inc. | Regulatory t cell epitopes |
| EP3622962A1 (en) * | 2018-09-14 | 2020-03-18 | advanceCOR GmbH | Short cyclic peptides for the treatment of graves' disease |
| EP3963335B1 (en) * | 2019-05-03 | 2024-08-21 | Epivax Therapeutics, Inc. | Neoantigens in cancer |
| AU2021243734A1 (en) | 2020-03-27 | 2022-09-01 | Biotest Ag | Protein comprising at least one regulatory T cell activating epitope |
| US11911414B2 (en) | 2020-03-27 | 2024-02-27 | Epivax Inc. | Regulatory T cell epitopes |
| CN111856020B (zh) * | 2020-06-19 | 2022-09-27 | 南方医科大学南方医院 | 乙型肝炎病毒（hbv）特异性t细胞检测方法及其应用 |
| WO2022036193A2 (en) * | 2020-08-13 | 2022-02-17 | Epivax, Inc. | Regulatory t cell epitopes |
| WO2022067076A1 (en) * | 2020-09-25 | 2022-03-31 | Epivax, Inc. | Retro-inverso regulatory t cell epitopes |
| CA3225927A1 (en) * | 2021-07-16 | 2023-01-19 | Vincent Dioszeghy | Immunotherapeutic method for increasing cashew tolerance in a subject |
| IL324608A (en) | 2023-05-19 | 2026-01-01 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| FR2556219B1 (fr) | 1983-12-07 | 1987-06-26 | Merieux Inst | Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5817308A (en) * | 1994-02-14 | 1998-10-06 | University Of Rochester | Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance |
| DE4425115A1 (de) | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Verfahren zur Modifizierung der Stabilität von Antikörpern |
| US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| EP0888125B1 (en) | 1996-03-20 | 2004-05-26 | Immunomedics, Inc. | GLYCOSYLATED IgG ANTIBODIES |
| US6090381A (en) * | 1997-02-11 | 2000-07-18 | Immunomedics, Inc. | Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope |
| EP0981548A4 (en) * | 1997-04-30 | 2005-11-23 | Enzon Inc | GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF |
| US6953675B2 (en) | 1997-11-06 | 2005-10-11 | Immunomedics, Inc. | Landscaped antibodies and antibody fragments for clinical use |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| DE60040147D1 (de) | 1999-05-28 | 2008-10-16 | Targeted Genetics Corp | Methoden und zusammensetzungen zur reduktion des tumor-nekrosis-faktor-spiegels (tnf) bei tnf-assoziierten erkrankungen |
| US6445840B1 (en) | 1999-05-28 | 2002-09-03 | Omm, Inc. | Micromachined optical switching devices |
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20020119492A1 (en) | 2000-07-10 | 2002-08-29 | Chirino Arthur J. | Protein design automation for designing protein libraries with altered immunogenicity |
| EP1368377A2 (en) * | 2001-03-15 | 2003-12-10 | MERCK PATENT GmbH | Modified interferon beta with reduced immunogenicity |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| CA2466592A1 (en) * | 2001-11-12 | 2003-05-22 | Koen Hellendoorn | Modified anti-tnf alpha antibody |
| ATE414534T1 (de) | 2001-12-05 | 2008-12-15 | Circassia Ltd | Immunotherapeutische methoden und systeme |
| AU2002364587A1 (en) | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2261250B1 (en) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
| AU2003244515A1 (en) | 2002-02-07 | 2003-09-02 | Novozymes Delta Limited | Albumin-fused anti-angiogenesis peptides |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| CA2485698C (en) | 2002-05-24 | 2012-03-27 | Jin Seog Seo | Peptide amidation process |
| WO2005056606A2 (en) * | 2003-12-03 | 2005-06-23 | Xencor, Inc | Optimized antibodies that target the epidermal growth factor receptor |
| DE60333228D1 (de) * | 2002-12-02 | 2010-08-12 | Amgen Fremont Inc | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen |
| CN1511958A (zh) * | 2002-12-31 | 2004-07-14 | 王小宁 | 一种筛选人组织相容性抗原(hla)的t细胞表面抗原肽的体系,及其在制备mhc-抗原肽多聚体中的应用 |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2005035575A2 (en) * | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| LT2857418T (lt) | 2004-02-06 | 2017-09-25 | University Of Massachusetts | Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas |
| ES2567634T3 (es) | 2004-02-09 | 2016-04-25 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina |
| ES2424643T3 (es) * | 2004-03-19 | 2013-10-07 | Merck Patent Gmbh | Proteínas bouganina modificadas, citotoxinas y procedimientos y usos de las mismas |
| CN1961003B (zh) * | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| KR20070057818A (ko) | 2004-08-03 | 2007-06-07 | 트랜스테크 파르마, 인크. | Ｒａｇｅ 융합 단백질 및 이의 사용 방법 |
| JP5188804B2 (ja) | 2004-08-03 | 2013-04-24 | トランステック ファーマ，インコーポレイティド | Ｒａｇｅ融合タンパク質及びその使用方法 |
| CU23504A1 (es) * | 2004-09-24 | 2010-04-13 | Ct Ingenieria Genetica Biotech | Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas |
| US7488804B2 (en) | 2005-02-02 | 2009-02-10 | The Regents Of The University Of California | Modified fusion molecules for treatment of allergic disease |
| ES2417133T3 (es) * | 2005-02-03 | 2013-08-06 | Antitope Limited | Anticuerpos y proteínas humanas |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| MX2008001865A (es) | 2005-08-12 | 2008-04-15 | Human Genome Sciences Inc | Proteinas de fusion de albumina. |
| CN100349921C (zh) * | 2005-11-17 | 2007-11-21 | 中国人民解放军第四军医大学 | 破伤风毒素t细胞表位多肽与人b淋巴细胞刺激因子融合蛋白及其制备 |
| EP2253644B1 (en) * | 2005-12-20 | 2013-10-16 | Bristol-Myers Squibb Company | Compositions and methods for producing a composition |
| KR101516823B1 (ko) * | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| GB0605735D0 (en) | 2006-03-22 | 2006-05-03 | Immunobiology Ltd | Composition and method for mediating an immune response |
| US8334365B2 (en) | 2006-06-07 | 2012-12-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AT503861B1 (de) † | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| EP2520935A3 (en) | 2006-08-09 | 2013-02-13 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| AU2008211227B2 (en) | 2007-01-30 | 2014-04-17 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
| AU2008261042A1 (en) | 2007-06-08 | 2008-12-11 | Dow Global Technologies Inc. | Expression of soluble antibody fragment by truncation of CH1 domain |
-
2008
- 2008-01-29 AU AU2008211227A patent/AU2008211227B2/en not_active Ceased
- 2008-01-29 EP EP20110177625 patent/EP2423220B1/en not_active Not-in-force
- 2008-01-29 AT AT08713321T patent/ATE525392T1/de not_active IP Right Cessation
- 2008-01-29 EP EP20120153174 patent/EP2450371B1/en not_active Not-in-force
- 2008-01-29 MX MX2015014429A patent/MX347197B/es unknown
- 2008-01-29 JP JP2009548278A patent/JP4866467B2/ja not_active Expired - Fee Related
- 2008-01-29 EP EP12153171A patent/EP2450369A1/en not_active Withdrawn
- 2008-01-29 CA CA2963138A patent/CA2963138C/en active Active
- 2008-01-29 EP EP12153166A patent/EP2450367A1/en not_active Withdrawn
- 2008-01-29 CN CN200880011016.5A patent/CN101687912B/zh not_active Expired - Fee Related
- 2008-01-29 KR KR1020097017996A patent/KR20100014871A/ko not_active Ceased
- 2008-01-29 WO PCT/US2008/001148 patent/WO2008094538A2/en not_active Ceased
- 2008-01-29 CA CA2677073A patent/CA2677073C/en active Active
- 2008-01-29 EP EP20110177630 patent/EP2423221B1/en not_active Not-in-force
- 2008-01-29 EP EP12153170A patent/EP2450368A1/en not_active Withdrawn
- 2008-01-29 KR KR1020177008095A patent/KR20170037677A/ko not_active Ceased
- 2008-01-29 CA CA3161849A patent/CA3161849A1/en active Pending
- 2008-01-29 CA CA2915168A patent/CA2915168C/en active Active
- 2008-01-29 KR KR1020147024226A patent/KR101722305B1/ko not_active Expired - Fee Related
- 2008-01-29 EP EP15153373.4A patent/EP2896630B1/en not_active Not-in-force
- 2008-01-29 US US12/021,832 patent/US7884184B2/en active Active
- 2008-01-29 EP EP20110177609 patent/EP2423219B1/en not_active Not-in-force
- 2008-01-29 CN CN202011190692.2A patent/CN112279911A/zh active Pending
- 2008-01-29 CN CN201310685046.7A patent/CN103755789B/zh not_active Expired - Fee Related
- 2008-01-29 EP EP12153164A patent/EP2450366A1/en not_active Withdrawn
- 2008-01-29 EP EP20120153177 patent/EP2450372B1/en not_active Not-in-force
- 2008-01-29 CN CN201610958012.4A patent/CN107011431B/zh not_active Expired - Fee Related
- 2008-01-29 CA CA3001783A patent/CA3001783C/en active Active
- 2008-01-29 CA CA3034396A patent/CA3034396C/en active Active
- 2008-01-29 EP EP08713321.1A patent/EP2125883B2/en not_active Not-in-force
- 2008-01-29 EP EP11177634.0A patent/EP2423222B2/en not_active Not-in-force
- 2008-01-29 EP EP12153173A patent/EP2450370A1/en not_active Withdrawn
- 2008-01-29 MX MX2009008230A patent/MX2009008230A/es active IP Right Grant
-
2009
- 2009-07-28 IL IL200129A patent/IL200129A/en active IP Right Grant
- 2009-07-30 MX MX2018015933A patent/MX2018015933A/es unknown
-
2010
- 2010-12-29 US US12/981,098 patent/US20110182921A1/en not_active Abandoned
-
2011
- 2011-11-11 JP JP2011247226A patent/JP5643739B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-30 JP JP2014154372A patent/JP6121369B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-17 US US14/857,693 patent/US10213496B2/en active Active
-
2016
- 2016-05-04 IL IL245478A patent/IL245478B/en active IP Right Grant
-
2017
- 2017-03-29 JP JP2017064298A patent/JP6472476B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-22 US US16/015,828 patent/US11045530B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,796 patent/US10925939B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,814 patent/US11045528B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,802 patent/US10925940B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,822 patent/US11045529B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,784 patent/US10751397B2/en active Active
- 2018-06-22 US US16/015,837 patent/US11045531B2/en not_active Expired - Fee Related
- 2018-10-16 US US16/161,674 patent/US10925941B2/en not_active Expired - Fee Related
- 2018-10-16 US US16/161,671 patent/US11045532B2/en not_active Expired - Fee Related
-
2019
- 2019-01-22 JP JP2019008352A patent/JP2019089793A/ja active Pending
- 2019-03-04 US US16/291,372 patent/US10925942B2/en not_active Expired - Fee Related
- 2019-03-04 US US16/291,658 patent/US10980867B2/en not_active Expired - Fee Related
- 2019-06-10 IL IL267186A patent/IL267186B/en active IP Right Grant
- 2019-08-02 US US16/530,104 patent/US20190351036A1/en not_active Abandoned
-
2021
- 2021-01-28 JP JP2021011596A patent/JP2021073255A/ja not_active Withdrawn
- 2021-04-21 US US17/236,463 patent/US11844826B2/en active Active
- 2021-04-21 US US17/236,534 patent/US12016909B2/en active Active
- 2021-04-22 JP JP2021072455A patent/JP2021107444A/ja active Pending
- 2021-04-22 JP JP2021072446A patent/JP2021107443A/ja active Pending
-
2022
- 2022-01-14 US US17/576,321 patent/US20220211827A1/en not_active Abandoned
- 2022-09-29 JP JP2022155804A patent/JP2022177270A/ja active Pending
-
2024
- 2024-03-06 JP JP2024033497A patent/JP2024059975A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010516290A5 (https=) | ||
| CN107148427B (zh) | 新型免疫原性肽 | |
| JP6484293B2 (ja) | Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法 | |
| CN103998056B (zh) | 用于接种抗金黄色葡萄球菌疫苗的方法和组合物 | |
| JP2015521467A5 (https=) | ||
| ES2373055T3 (es) | Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno. | |
| De Amicis et al. | Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes | |
| KR20220132023A (ko) | 신규 면역원성 CD1d 결합 펩티드 | |
| JP2022513019A (ja) | 新規の酸化還元酵素モチーフを有する免疫原性ペプチド | |
| JP2006506942A5 (https=) | ||
| WO2022071513A1 (ja) | ＳＡＲＳ－ＣｏＶ－２に対する改良型ＤＮＡワクチン | |
| US12414987B2 (en) | Phosphorylated polypeptide antigen vaccine, preparation method therefor and application thereof | |
| JP2010535504A5 (https=) | ||
| CN115916805A (zh) | 具有延伸的氧化还原酶基序的免疫原性肽 | |
| NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same | |
| CN101455846B (zh) | 脱乙酰壳聚糖递送系统组装的结核基因疫苗及其制备和应用 | |
| CN103596971A (zh) | 通过删除由nkt细胞识别的表位来调整抗原免疫原性 | |
| WO2018049130A1 (en) | Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of infectious diseases | |
| EP1668036A2 (fr) | Procede a haut rendement pour l' obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine | |
| WO2017177910A1 (zh) | 增强抗肿瘤免疫反应的新型免疫策略和免疫组合物 | |
| KR20240015672A (ko) | 면역원성 펩티드를 사용한 개선된 치료 방법 | |
| EP3574915A1 (en) | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity | |
| CA2795308A1 (en) | Parapoxvirus expressing the vp60 major capsid protein of the rabbit haemorrhagic disease virus | |
| US20240148864A1 (en) | Polysaccharide adjuvants for virus vaccines | |
| US20230218741A1 (en) | Sars-cov-2 vaccines for population-scale immunity |